Cerebrovascular contributions to cognitive impairment in Lewy body dementias

脑血管对路易体痴呆认知障碍的影响

• 批准号: 10560481
• 负责人: Sephira Ryman
• 金额: $ 18.1万
• 依托单位: LOVELACE BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-02-15 至 2025-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10560481
• 关键词: Accounting; Address; Age; Amyloid beta-42; Amyloid beta-Protein; Biological Markers; Blood; Blood Vessels; Blood capillaries; Cerebrovascular Disorders; Clinic; Clinical; Cognitive; Collaborations; Dementia; Dementia with Lewy Bodies; Deposition; Development; Disease; Early Diagnosis; Early identification; Etiology; Evaluation; Exhibits; Foundations; Frequencies; Functional disorder; Goals; Health; Imaging Techniques; Impaired cognition; Impairment; Intervention; Label; Lewy Body Dementia; Lewy Body Disease; Literature; Location; Magnetic Resonance Imaging; Measurement; Measures; Methodology; Monitor; Multimodal Imaging; Nerve Degeneration; Neurobehavioral Manifestations; Outcome; Parkinson' s Dementia; Patients; Perfusion; Plasma; Process; Research; Sensitivity and Specificity; Severities; Stratification; Threonine; Time; Tissue imaging; Translations; Travel; United States National Institutes of Health; White Matter Hyperintensity; Work; alpha synuclein; arteriole; cardiovascular risk factor; cerebrovascular; cognitive impairment in Parkinson' s; cohort; disability; early detection biomarkers; efficacious treatment; functional disability; innovation; magnetic resonance imaging biomarker; neuropathology; neurovascular; novel; protein aggregation; recruit; response; sex; tau Proteins; tau-1

Project Summary / Abstract Cognitive decline in Lewy body dementias [Parkinson’s Disease Dementia (PDD) and Dementia with Lewy Bodies (DLB)] causes significant functional impairment and does not respond well to existing treatments. Perhaps the largest challenge for developing efficacious treatments in these diseases is the lack of objective biomarkers for early identification and stratification of PDD/DLB patients based on the location and extent of neuropathological processes. Cerebrovascular impairment may be an important factor to capture early in the disease course as there are numerous opportunities for intervention. However, there are several limitations of the prior research, including: 1) objective measurement of cerebrovascular functions, 2) evaluation of the frequency and consistency in subject specific cerebrovascular abnormalities, 3) examination of the impact of cerebrovascular dysfunction on clinical presentation, and 4) examination of the relationship between cerebrovascular dysfunction and AD plasma biomarkers. The current study addresses these gaps in the literature and leverages innovative magnetic resonance imaging measures, including: cerebrovascular reactivity (CVR), the ability of the arterioles and capillaries to dilate in response to a vasodilatory challenge, and arterial transfer time (ATT) - the travel time of labeled blood to the imaged tissue. This study is both clinically and methodologically innovative as we use state of the art multimodal imaging to quantify several aspects of cerebrovascular function and integrate biospecimen analyses to answer key clinical questions. Specifically, PDD (N = 20), DLB (N = 20), and healthy controls (HC, N = 20) matched on age and sex will be recruited to evaluate the sensitivity and specificity of novel relative to established MRI cerebrovascular biomarkers and frequency of abnormal cerebrovascular functions in patient groups (Aim 1). We will then evaluate the relationships between cerebrovascular abnormalities, AD plasma biomarkers, and cognitive symptoms (Aim 2). At the conclusion of this successful application, we will identify which cerebrovascular functions are altered in PDD/DLB, the frequency of cerebrovascular abnormalities in PDD/DLB, and the relationship between cerebrovascular abnormalities, AD plasma biomarkers, and cognitive outcomes. This information is crucial to developing interventions for these disorders as potentially cerebrovascular dysfunction may occur early and provide ample opportunity for intervention. Additionally, in line with the objectives outlined in PAS-19-392, this project will establish an initial cohort of Lewy body dementia patients that can be expanded through a competitive R01 application to evaluate longitudinal change in cerebrovascular functioning in Lewy body disease across the cognitive spectrum (e.g. in PD-MCI, prodromal DLB). As part of the current project, the PI will engage in professional development efforts through several local NIH Centers, enhancing opportunities for networking, collaboration, and retention in the field.

项目总结/摘要 路易体痴呆的认知功能下降[帕金森病痴呆（PDD）和路易体痴呆] 身体（DLB）]导致严重的功能障碍，对现有的治疗反应不佳。 也许在这些疾病中开发有效治疗方法的最大挑战是缺乏客观的 用于PDD/DLB患者的早期识别和分层的生物标志物， 神经病理过程脑血管损伤可能是早期捕获的重要因素， 疾病的过程，因为有许多机会进行干预。然而，有几个限制， 现有的研究包括：1）脑血管功能的客观测量，2） 受试者特定脑血管异常的频率和一致性，3）检查 脑血管功能障碍的临床表现，和4）检查之间的关系 脑血管功能障碍和AD血浆生物标志物。目前的研究解决了这些差距， 文献，并利用创新的磁共振成像措施，包括：脑血管反应性 (CVR)，小动脉和毛细血管响应血管舒张挑战而扩张的能力，以及动脉 转移时间（ATT）-标记血液到成像组织的传输时间。这项研究是临床和 方法上的创新，因为我们使用最先进的多模态成像来量化的几个方面， 脑血管功能和综合生物样本分析，以回答关键的临床问题。具体而言，PDD 将招募在年龄和性别上匹配的DLB（N = 20）、DLB（N = 20）和健康对照（HC，N = 20）以评价 新的相对于已建立的MRI脑血管生物标志物的敏感性和特异性以及 异常脑血管功能的患者组（目的1）。然后我们将评估 脑血管异常、AD血浆生物标志物和认知症状（目的2）。结束时 这一成功的应用，我们将确定哪些脑血管功能在PDD/DLB中改变， PDD/DLB中脑血管异常的频率，以及脑血管异常与PDD/DLB的关系。 异常、AD血浆生物标志物和认知结果。这些信息对于开发 对这些疾病的干预，因为潜在的脑血管功能障碍可能发生在早期， 干预的机会。此外，根据PAS-19-392中概述的目标，该项目将 建立路易体痴呆患者的初始队列，可通过竞争性R 01进行扩展 应用于评估路易体病脑血管功能的纵向变化 认知谱（例如PD-MCI、前驱DLB）。作为当前项目的一部分，PI将参与 通过几个地方NIH中心的专业发展努力，增加联网的机会， 合作，并在现场保留。